ALPCO Launches Rat and Mouse Proinsulin ELISA Kits
ALPCO Immunoassays has developed two new low-sample volume ELISAs for the quantitative
analysis of total proinsulin (I and II) in rats and mice.
Salem, NH, January 26, 2010 --(PR.com)-- ALPCO Immunoassays has developed two new low-sample
volume ELISAs for the quantitative analysis of total proinsulin (I and II) in rats and mice. These methods
were developed using synthetic rat and mouse proinsulin I and II expressed in bacteria and purified from
inclusion bodies, and were first introduced in an abstract presented at the Upper Midwest Islet Club
Meeting in June 2009.
Both the Rat Proinsulin ELISA and Mouse Proinsulin ELISA allow for the direct quantification of total
proinsulin (I & II) in serum. Each kit requires only 10 µl of serum, giving researchers the opportunity to
measure multiple analytes from a single sample collection. The evaluation of a representative sample
population of commonly used mouse and rat strains showed that > 90% of samples fell within the
dynamic range of the respective assays, illustrating their utility in the field.
A hallmark of these new assay systems are their defined cross reactivity with both proinsulin I and II.
Peter Wunderli, PhD, Laboratory Operations Manager at ALPCO, remarks on the significance of this
advancement, “Rat proinsulin, as for mouse, is expressed as two isoforms. No one knows whether
isoform expression is individually influenced by the disease. Until that is established, there is a need to be
able to measure the total proinsulin. Our kits do that with excellent specificity and robustness.”
Several factors, not the least of which being the variability in expression of proinsulin I and II between
mice and rats, makes the ALPCO species-specific assay kits the most attractive option for researchers
expecting to quantify total proinsulin in their pre-clinical models.
While research has established that the total ratio of circulating proinsulin relative to insulin and c-peptide
is altered in the diabetic and pre-diabet